Assessment of Platelet Response to Aspirin Therapy and Hemocompatibility-Related Adverse Events in HeartMate 3 Left Ventricular Assist Device Recipients

Purpose: Patients receiving left ventricular assist devices (LVADs) typically undergo anticoagulation and aspirin (ASA) therapy. The HeartMate 3 (HM3) has shown promise in reducing hemocompatibility-related adverse events (HRAEs) like stroke, thrombosis and bleeding. However, it remains uncertain whether ASA responsiveness impacts the incidence of HRAEs and if ASA sensitivity changes during HM3 support.

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , H. Al Asadi, T. Abart, C. Schwarz, H. Schima, J. Riebandt, C. Marko, D. Wiedemann, B. Messner, D. Zimpfer Source Type: research